BioSpace News Archive

Elderly and obese patients receiving OLINVYK are not at increased risk for respiratory depression, compared to younger and non-obese patients, based on exploratory analysis

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the first quarter of 2021 on Wednesday, May 26 th , 2021.

IND cleared for Phase 2 study of CGT9486, a selective mutant KIT inhibitor, in Advanced Systemic Mastocytosis patients John Robinson, PhD appointed as Chief Scientific Officer to lead newly created Cogent Research team Evan Kearns, JD joined Cogent as Chief Legal Officer Ended Q1 2021 with $230.7 million in cash, sufficient to fund operations into 2024

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will be participating in a fireside chat at the 2021 RBC Capital Markets Global

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company announces that NP-120 (Ifenprodil) reduced interleukin 6 (IL-6) with statistical significance in its recent Ifenprodil Phase 2b/3 COVID-19 trial, which may be informative for the Company’s ongoing Phase 2 trial of Ifenprodil for idiopathic pulmonary fibrosis (IPF)

Biomarck Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company focused on developing peptides that inhibit MARCKS to treat patients with inflammatory diseases, today announced that data from a Phase II placebo-controlled clinical study of BIO-11006, the Company’s lead peptide, will be presented during the 2021 ATS (American Thoracic Society) Annual Meeting, May 14 – 19, 2021.

Hansa Biopharma AB has on May 12, 2021 held its Annual General Meeting. In order to mitigate the spread of Covid-19, the Annual General Meeting was conducted by advance voting only, without physical presence of shareholders, proxies and third parties.

- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in upcoming investor conferences: 2021 RBC Capital Markets Global Healthcare Virtual Conference Date: Wednesday, May 19, 2021 Time: 11:30 AM – 11:55 AM EDT

Findings to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy Data demonstrate durable expression in CNS and may represent a new single-dose therapeutic strategy for treating various tauopathies

Cedars-Sinai Veteran Physician Joins Four Additional Clinical, Oncology and Cannabinoid Experts to Guide the Company’s Research and Scientific Programs